Compare AHCO & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHCO | WGS |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Medical/Nursing Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2017 | N/A |
| Metric | AHCO | WGS |
|---|---|---|
| Price | $10.84 | $59.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $13.50 | ★ $120.71 |
| AVG Volume (30 Days) | ★ 1.3M | 720.6K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,244,857,000.00 | N/A |
| Revenue This Year | $9.00 | $29.98 |
| Revenue Next Year | $6.93 | $25.92 |
| P/E Ratio | ★ N/A | $1,251.58 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.51 | $32.21 |
| 52 Week High | $13.43 | $170.87 |
| Indicator | AHCO | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 55.80 | 46.32 |
| Support Level | $10.80 | $55.76 |
| Resistance Level | $12.87 | $63.31 |
| Average True Range (ATR) | 0.40 | 4.22 |
| MACD | 0.05 | -0.95 |
| Stochastic Oscillator | 55.61 | 16.06 |
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The company generates majority of its revenue from the Sleep Health segment. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.